A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection

Clinical and Vaccine Immunology

Volumn 14, Issue 4, 2007, Pages 382-390

  Fabrizio, Kevin ^a   Groner, Abraham ^a   Boes, Marianne ^b   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; IMMUNOGLOBULIN M; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A7; PARAPROTEIN; PENICILLIN G; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; STREPTOCOCCUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BACTEREMIA; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULIN M; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; PNEUMOCOCCAL INFECTIONS;

EID: 34248382529     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00374-06     Document Type: Article

References (56)

1. Austriam, R., and J. Gold. 1964. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med. 60: 759-776.
2. Blue, C. E., G. K. Paterson, A. R. Kerr, M. Berge, J. P. Claverys, and T. J. Mitchell. 2003. ZmpB, a novel virulence factor of Streptococcus pneumoniae that induces tumor necrosis factor alpha production in the respiratory tract. Infect. Immun. 71:4925-4935.
3. Boes, M., C. Esau, M. B. Fischer, T. Schmidt, M. Carroll, and J. Chen. 1998. Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. J. Immunol. 160:4776-4787.
4. Boes, M., A. P. Prodeus, T. Schmidt, M. C. Carroll, and J. Chen. 1998. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J. Exp. Med. 188:2381-2386.
5. Bogaert, D., M. Sluijter, R. De Groot, and P. W. Hermans. 2004. Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine. Vaccine 22:4014-4020.
6. Brown, J. S., T. Hussell, S. M. Gilliland, D. W. Holden, J. C. Paton, M. R. Ehrenstein, M. J. Walport, and M. Botto. 2002. The classical pathway is the dominant complement pathway required for innate immunity to Streptococ cus pneumoniae infection in mice. Proc. Natl. Acad. Sci. USA 99:16969-16974.
7. Buchwald, U. K., and L. Pirofski. 2003. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr. Pharm. Des. 9:945-968.
8. Burns, T., M. Abadi, and L. Pirofski. 2005. Modulation of the lung inflammatory response to serotype 8 pneumococcus infection by a human monoclonal immunoglobulin M to serotype 8 capsular polysaccharide. Infect. Immun. 73:4530-4538.
9. Burns, T., Z. Zhong, M. Steinitz, and L. A. Pirofski. 2003. Modulation of polymorphonuclear cell interleukin-8 secretion by human monoclonal antibodies to type 8 pneumococcal capsular polysaccharide. Infect. Immun. 71:6775-6783.
10. Casadevall, A., and L. Pirofski. 2003. Antibody mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 24:474-478.
11. Casadevall, A, and L. A. Pirofski. 2006. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv. Immunol. 91:1-44.
12. Casadevall, A., and M. D. Scharff. 1995. Return to the past: the case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 21:150-161.
13. Chang, Q., Z. Zhong, A. Lees, M. Pekna, and L. Pirofski. 2002. Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin loci. Infect. Immun. 70:4977-4986.
14. Charan, S., and R. M. Zinkernagel. 1986. Antibody mediated suppression of secondary IgM response in nude mice against vesicular stomatitis virus. J. Immunol. 136:3057-3061.
15. Committee on New Directions in the Study of Antimicrobial Therapeutics: Immunomodulations. 2006. Treating infectious diseases in the microbial world: report of two workshops on novel antimicrobial therapies. National Academies Press, Washington, DC.
16. Dallaire, F., N. Ouellet, Y. Bergeron, V. Turmel, M. C. Gauthier, M. Simard, and M. G. Bergeron. 2001. Microbiological and inflammatory factors associated with the development of pneumococcal pneumonia. J. Infect. Dis. 184:292-300.
17. Diamond, M. S., B. Shrestha, A. Marri, D. Mahan, and M. Engle. 2003. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77:2578-2586.
18. Diamond, M. S., E. M. Sitati, L. D. Friend, S. Higgs, B. Shrestha, and M. Engle. 2003. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 198:1853-1862.
19. Dockrell, D. H., H. M. Marriott, L. R. Prince, V. C. Ridger, P. G. Ince, P. G. Hellewell, and M. K. Whyte. 2003. Alveolar macrophage apoptosis contributes to pneumococcal clearance in a resolving model of pulmonary infection. J. Immunol. 171:5380-5388.
20. Frimodt-Moller, N., O. Sebbesen, and V. Frolund Thomsen. 1983. The pneumococcus and the mouse protection test: importance of the lag phase in vivo. Chemotherapy 29:128-134.
21. Gaini, S., O. G. Koldkjaer, C. Pedersen, and S. S. Pedersen. 2006. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit. Care 10:R53.
22. Giebink, G. S., J. E. Foker, Y. Kim, and G. Schiffman. 1980. Serum antibody and opsonic responses to vaccination with pneumococcal capsular polysaccharide in normal and splenectomized children. J. Infect. Dis. 141:404-412.
23. Green, L. L. 1999. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 231:11-23.
24. Heffron, R. 1939. Pneumonia, with special reference to pneumococcus lobar pneumonia, p. 805-921. Harvard University Press, Cambridge, MA.
25. Kadioglu, A., W. Coward, M. J. Colston, C. R. Hewitt, and P. W. Andrew. 2004. CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect. Immun. 72:2689-2697.
26. Kemp, K., H. Bruunsgaard, P. Skinhoj, and P. B. Klarlund. 2002. Pneumococcal infections in humans are associated with increased apoptosis and trafficking of type 1 cytokine-producing T cells. Infect. Immun. 70:5019-5025.
27. Kirby, A. C., J. G. Raynes, and P. M. Kaye. 2005. The role played by tumor necrosis factor during localized and systemic infection with Streptococcus pneumoniae. J. Infect. Dis. 191:1538-1547.
28. Knudsen, J. D., I. Odenholt, H. Erlendsdottir, M. Gottfredsson, O. Cars, N. Frimodt-Moller, F. Espersen, K. G. Kristinsson, and S. Gudmundsson. 2003. Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models. Antimicrob. Agents Chemother. 47:2499-2506.
29. Kolibab, K., S. L. Smithson, B. Rabquer, S. Khuder, and M. A. Westerink. 2005. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoire. Infect. Immun. 73:7465-7476.
30. Kolibab, K., S. L. Smithson, A. K. Shriner, S. Khuder, S. Romero-Steiner, G. M. Carlone, and M. A. Westerink. 2005. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults. I. Antibody concentrations, avidity and functional activity. Immun. Ageing 2:10.
31. Kroon, F. P., J. T. van Dissel, E. Ravensbergen, P. H. Nibbering, and R. van Furth. 2000. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 19:886-894.
32. Lakshman, R., C. Murdoch, G. Race, R. Burkinshaw, L. Shaw, and A. Finn. 2003. Pneumococcal nasopharyngeal carriage in children following heptavalent pneumococcal conjugate vaccination in infancy. Arch. Dis. Child. 88: 211-214.
33. Lexau, C. A., R. Lynfield, R. Danila, T. Pilishvili, R. Facklam, M. M. Farley, L. H. Harrison, W. Schaffner, A. Reingold, N. M. Bennett, J. Hadler, P. R. Cieslak, and C. G. Whitney. 2005. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294:2043-2051.
34. Lieu, T. A., G. T. Ray, S. B. Black, J. C. Butler, J. O. Klein, R. F. Breiman, M. A. Miller, and H. R. Shinefield. 2000. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 283:1460-1468.
35. Malley, R., K. Trzcinski, A. Srivastava, C. M. Thompson, P. W. Anderson, and M. Lipsitch. 2005. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc. Natl. Acad. Sci. USA 102:4848-4853.
36. Moore, L. J., A. C. Pridmore, S. K. Dower, and R. C. Read. 2003. Penicillin enhances the toll-like receptor 2-mediated proinflammatory activity of Streptococcus pneumoniae. J. Infect. Dis. 188:1040-1048.
37. Moore, L. J., A. C. Pridmore, S. K. Dower, and R. C. Read. 2004. The glycopeptide vancomycin does not enhance toll-like receptor 2 (TLR2) activation by Streptococcus pneumoniae. J. Antimicrob. Chemother. 54:76-78.
38. Nahm, M. H., J. V. Olander, and M. Magyarlaki. 1997. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococ cus pneumoniae. J. Infect. Dis. 176:698-703.
39. Nuermberger, E. L., and W. R. Bishai. 2004. Antibiotic resistance in Streptococcus pneumoniae: what does the future hold? Clin. Infect. Dis. 38(Suppl. 4):S363-S371.
40. Pirofski, L., and A. Casadevall. 2006. Immunomodulators as an antimicrobial tool. Curr. Opin. Microbiol. 9:489-495.
41. Pirofski, L., and A. Casadevall. 1998. The use of licensed vaccines for active immunization of the immunocompromised host. Clin. Microbiol. Rev. 11:1-26.
42. Rijneveld, A. W., G. P. van den Dobbelsteen, S. Florquin, T. J. Standiford, P. Speelman, L. Van Alphen, and T. van der Poll. 2002. Roles of interleukin-6 and macrophage inflammatory protein-2 in pneumolysin-induced lung inflammation in mice. J. Infect. Dis. 185:123-126.
43. Robbins, J. B., R. Schneerson, and S. C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1387-1398.
44. Romero-Steiner, S., C. Frasch, N. Conception, D. Goldblatt, H. Kayhty, M. Vakevainen, C. Laferriere, D. Wauters, M. H. Nahm, M. F. Schinsky, B. D. Plikaytis, and G. M. Carlone. 2003. Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin. Diagn. Lab. Immunol. 10:1019-1024.
45. Russell, N., J. R. Corvalan, M. L. Gallo, C. G. Davis, and L. Pirofski. 2000. Production of protective human anti-pneumococcal antibodies by transgenic mice with human immunoglobulin loci. Infect. Immun. 68:1820-1826.
46. Schmeck, B., S. Huber, K. Moog, J. Zahlten, A. C. Hocke, B. Opitz, S. Hammerschmidt, T. J. Mitchell, M. Kracht, S. Rosseau, N. Suttorp, and S. Hippenstiel. 2006. Pneumococci induced TLR- and Rac1-dependent NF-kappaB-recruitment to the IL-8 promoter in lung epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 290:L730-L737.
47. Stephens-Romero, S. D., A. J. Mednick, and M. Feldmesser. 2005. The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy. Infect. Immun. 73:114-125.
48. Sullivan, J. B. 1987. Past, present, and future immunotherapy of snake venom poisoning. Ann. Emerg. Med. 16:938-944.
49. Takashima, K., K. Tateda, T. Matsumoto, Y. Iizawa, M. Nakao, and K. Yamaguchi. 1997. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect. Immun. 65:257-260.
50. Tomasz, A. 1999. New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae. Am. J. Med. 107(1A):55S-62S.
51. Usinger, W. R., and A. H. Lucas. 1999. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect. Immun. 67:2366-2370.
52. van der Poll, T., C. V. Keogh, X. Guirao, W. A. Buurman, M. Kopf, and S. F. Lowry. 1997. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J. Infect. Dis. 176:439-444.
53. van Rossum, A. M., E. S. Lysenko, and J. N. Weiser. 2005. Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneu moniae in a murine model. Infect. Immun. 73:7718-7726.
54. Vernacchio, L., E. J. Neufeld, K. MacDonald, S. Kurth, S. Murakami, C. Hohne, M. King, and D. Molrine. 1998. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J. Pediatr. 133: 275-278.
55. Wright, T. W., C. J. Johnston, A. G. Harmsen, and J. N. Finkelstein. 1999. Chemokine gene expression during Pneumocystis carinii-driven pulmonary inflammation. Infect. Immun. 67:3452-3460.
56. Zhong, Z., T. Burns, Q. Chang, M. Carroll, and L. Pirofski. 1999. Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide. Infect. Immun. 67:4119-4127.